CTXR News and Press, Citius Pharmaceuticals Inc. From 10/21/25

Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules PR Newswire CRANFORD, N.J. , Oct. 21, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a bioph...

Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules PR Newswire CRANFORD, N.J. , Oct. 21, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical ...

Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch PR Newswire McKesson joins leading distribution service providers as authorized U.S. distributor of LYMPHIR CRANFORD, N.J. , Oct. 20, 2025 /PRNewswire/ -- Citius O...

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences PR Newswire LD Micro Main Event XIX, October 19-21, 2025 2025 Maxim Growth Summit, October 22-23, 2025 The Think Equity Conference, October 30, 2025 CRANFORD, N.J. , ...

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™ PR Newswire EVERSANA  to provide integrated commercialization services, enhancing launch readiness and market entry for differentiated Cutaneous T-...

Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement PR Newswire CRANFORD, N.J. , Sept. 10, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of ...

2025-09-09 08:42:16 ET More on Citius Pharmaceuticals, Citius Oncology Citius Oncology: Is A Lymphir Launch Coming Too Late? Citius Oncology announces pricing of $9 million public offering Cencora distribution deal boosts Citius shares Seeking Alpha’s ...

Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement PR Newswire CRANFORD, N.J. , Sept. 9, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of C...

2025-08-12 16:43:51 ET More on Citius Pharmaceuticals Citius Oncology announces pricing of $9 million public offering Cencora distribution deal boosts Citius shares Seeking Alpha’s Quant Rating on Citius Pharmaceuticals Historical earnings data for Cit...

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update PR Newswire $12.5 million in gross financings raised during the quarter, with an additional $9 million raised by Citius Oncology in July 2025 , to facilita...